desvenlafaxine (Pristiq, Khedezla)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

  • Medical and Pharmacy Editor: William C. Shiel Jr., MD, FACP, FACR
    William C. Shiel Jr., MD, FACP, FACR

    William C. Shiel Jr., MD, FACP, FACR

    Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.

Understanding Depression Slideshow

PRESCRIBED FOR: Desvenlafaxine is used for the treatment of major depression.

DOSING: The recommended dose of desvenlafaxine is 50 mg daily, with or without food. Tablets should be taken whole and should not be crushed, divided, chewed, or dissolved. Doses greater than 50 mg are not more effective but cause more side effects.

DRUG INTERACTIONS: All SNRIs, including desvenlafaxine, should not be taken with any of the monoamine oxidase inhibitor (MAOI) class of antidepressants, for example, isocarboxazid (Marplan), phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Eldepryl), and procarbazine (Matulane) or other drugs that inhibit monoamine oxidase [for example, linezolid (Zyvox)]. Such combinations may lead to confusion, high blood pressure, tremor, hyperactivity, coma, and death. Desvenlafaxine should not be administered within 14 days after stopping MAOIs and MAOIs should not be administered within 7 days of stopping desvenlafaxine.

Similar reactions may occur if desvenlafaxine is combined with other SNRIs, selective serotonin reuptake inhibitors (for example, fluoxetine [Prozac] or paroxetine [Paxil]) or other drugs that increase serotonin in the brain, for example, tryptophan, St. John's wort, meperidine (Demerol) or tramadol (Ultram).

Medically Reviewed by a Doctor on 8/6/2014

Quick GuideDepression Hurts: Physical Symptoms of Depression

Depression Hurts: Physical Symptoms of Depression
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Depression Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors